Condition: Breast Cancer · Refractory Breast Carcinoma · Sponsor: Sun Yat-sen University
This multicenter, open-label, randomized phase III trial is designed to study the efficacy and safety of organoid-guided personalized treatment （OGPT）versus treatment of physician's choice (TPC) in previously treated refractory breast cancer.
This description comes directly from the study's public registry record.
Yanxia Shi · 020-87343368 · shiyx@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Yanxia Shi | Guangzhou, None Selected, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06268652